Enzon Pharmaceuticals, Inc. (ENZN)
OTCMKTS: ENZN · Delayed Price · USD
0.00 (0.00%)
Jun 21, 2024, 3:42 PM EDT - Market closed

Company Description

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations.

Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.

The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002.

Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Enzon Pharmaceuticals, Inc.
Country United States
Founded 1981
IPO Date Feb 15, 1984
Industry Biotechnology
Sector Healthcare
CEO Richard L. Feinstein CPA

Contact Details

20 Commerce Drive, Suite 135
Cranford, New Jersey 07016
United States
Phone 732-980-4500
Website enzon.com

Stock Details

Ticker Symbol ENZN
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000727510
CUSIP Number 293904108
ISIN Number US2939041081
Employer ID 22-2372868
SIC Code 2836

Key Executives

Name Position
Richard L. Feinstein Chief Executive Officer, Chief Financial Officer and Company Secretary

Latest SEC Filings

Date Type Title
Jun 14, 2024 8-K Current Report
May 22, 2024 8-A12G/A Filing
May 22, 2024 8-K Current Report
May 10, 2024 10-Q Quarterly Report
Apr 26, 2024 10-K/A [Amend] Annual report
Mar 20, 2024 10-K Annual Report
Jan 5, 2024 8-K Current Report
Nov 9, 2023 10-Q Quarterly Report
Aug 7, 2023 10-Q Quarterly Report
Jun 14, 2023 8-K Current Report